Cocrystal Pharma (NASDAQ:COCP) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Cocrystal Pharma (NASDAQ:COCP) announced its quarterly earnings data on Tuesday. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01, FiscalAI reports.

Cocrystal Pharma Stock Up 1.0%

Cocrystal Pharma stock opened at $1.02 on Thursday. Cocrystal Pharma has a 12 month low of $0.86 and a 12 month high of $2.67. The stock has a market cap of $14.06 million, a P/E ratio of -1.29 and a beta of 1.18. The company’s fifty day simple moving average is $1.01 and its 200-day simple moving average is $1.06.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Insider Activity

In other news, Director Phillip Md Et Al Frost acquired 50,000 shares of Cocrystal Pharma stock in a transaction that occurred on Friday, February 6th. The stock was purchased at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the transaction, the director owned 1,888,551 shares in the company, valued at approximately $1,794,123.45. This trade represents a 2.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 28.14% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC purchased a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.